The OPT Congress 2026 serves as a premier gathering for professionals in oligonucleotide, mRNA, and peptide therapeutics. Now in its eleventh year, the event facilitates the transition of innovative science into life-changing medicines. Furthermore, the updated agenda features a new conference dedicated to peptides and emerging drug conjugates. Specifically, attendees will explore sixty scientific presentations covering AI-driven design and scalable manufacturing. Additionally, notable plenary speakers include Timothy Yu, Brenda Bass, Debra Miller, and Weimin Wang. Meanwhile, the program offers short courses and case studies regarding circular RNA and extrahepatic delivery. Consequently, experts from biotech and academia can collaborate on regulatory insights and technological breakthroughs. Therefore, this forum remains essential for those advancing therapeutic programs from bench to bedside.